Tolerability and Efficacy of the First-InClass Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results Daver, N., Vyas, P., Kambhampati, S., Al Malki, M., Larson, R., Asch, A., Mannis, G., Chai-Ho, W., Tanaka, T., Bradley, T., Jeyakumar, D., Wang, E., Xing, G., Chao, M., Ramsingh, G., Renard, C., Lal, I., Zeidner, J., Sallman, D. CIG MEDIA GROUP, LP. 2022: S253-S254

View details for Web of Science ID 000897948100179